Ozempic and Xtandi Among Top 15 Drugs Selected for U.S. Medicare Price Negotiations
The U.S. Department of Health and Human Services (HHS),through the centers for Medicare & Medicaid Services (CMS),has unveiled the next phase of its groundbreaking Medicare drug price negotiation program. this initiative, part of the Inflation Reduction Act, targets 15 additional drugs covered under Medicare Part D, with negotiations set to begin in 2025 and new … Read more
